An Elevated Value of Troponin I, Troponin T, CK-MB, and/or Myoglobin
Troponin I or T is now widely used over other markers for acute MI in the absence of other markers.
Any elevation can indicate myocyte damage; interpret results with defined institutional cutoffs for myocardial infarction.
Suggested Additional Lab Testing
Appropriate follow-up testing with troponin level.
Test as appropriate to rule out causes of increased troponin not caused by cardiac ischemia.
If ECG is abnormal in the presence of positive markers, this is strongly indicative for AMI.
If ECG is normal or shows a pattern not indicative for AMI with a suggestive clinical picture for MI, do serial testing for troponin pressure sensation within the chest with appropriate radiation of pain, which is suggestive of AMI.
Rule out other potential causes of an elevated troponin.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Endocrinology Advisor Articles
- Effect of Sugar-Sweetened Beverages on Obesity Development
- Denosumab May Increase BMD in Women With Primary Hyperparathyroidism
- Risk Factors for Diabetes May Be Identified 20 Years Before Diagnosis
- T2D May Play a Protective Role Against Developing Aortic Diseases
- Metformin and PCOS: Improving Menstrual Cycle and Hormone Profiles
- Metformin Safe in T2D With Moderate to Severe Chronic Kidney Disease
- SGLT2 Inhibitors Show High Cardiovascular- and Renal-Protective Effects in T2D
- Type 2 Diabetes Insulin Initiation: Predictors Identified
- Two New Diabetes Medications Now Available
- Managing Acute Pain in Patients With Severe Obesity
- Risk for Congenital Malformations With Antithyroid Drugs
- Occupational Therapy May Benefit Young Adults With Diabetes
- Weight Loss May Improve Pain in Patients With Obesity
- Prior Authorizations Are Creating a Challenge for Clinicians
- Effect of Biologic DMARDs on Spinal Fracture Risk in Ankylosing Spondylitis